Active — Not RecruitingNot Applicable

Serum IGF-1 and IGF-1Ec in Malignancy Assessment

Turkey (Türkiye)100 participantsStarted 2025-04-01

Plain-language summary

This cross-sectional study investigates the relationship between serum IGF-1 and IGF-1Ec (E-peptide/MGF) levels and tumor burden in patients with solid tumors. By analyzing serum samples using ELISA and correlating them with clinical data such as tumor stage, size, metastasis, and lymph node involvement, the study aims to explore whether these biomarkers-particularly IGF-1Ec and the IGF-1Ec/IGF-1 ratio-can reflect tumor progression and serve as potential prognostic indicators.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed diagnosis of a solid tumor * Clinically stable condition, prior to chemotherapy or during standard follow-up * Ability to provide informed consent Exclusion Criteria: * Hematological malignancies (e.g., leukemia, lymphoma) * Acute or chronic liver or kidney failure * Current use (within 1 month) of corticosteroids, growth hormone, or medications affecting IGF-1 levels * Pregnancy or lactation * Coagulopathy or severe anemia preventing safe venipuncture

What they're measuring

IGF-1 and IGF-1Ec levels

Timeframe: From enrollment to 6 month

Trial details

NCT IDNCT07151807

SponsorÇanakkale Onsekiz Mart University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12

View on ClinicalTrials.gov More Cancer trials